These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DELAWARE
|
|
95-4405754
|
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
Large accelerated filer
o
|
|
Accelerated filer
x
|
|
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
o
|
|
|
ACACIA RESEARCH CORPORATION
|
|||
|
Table Of Contents
|
|||
|
|
|
|
|
|
Part I.
|
Financial Information
|
|
|
|
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 2.
|
||
|
|
|
|
|
|
|
Item 3.
|
||
|
|
|
|
|
|
|
Item 4.
|
||
|
|
|
|
|
|
|
|
|
|
|
Part II.
|
Other Information
|
||
|
|
|
|
|
|
|
Item 1A.
|
Risk Factors
|
|
|
|
|
|
|
|
|
Item 6.
|
||
|
|
|
|
|
|
|
|
|
|
|
Signatures
|
|
||
|
|
|
|
|
|
Exhibit Index
|
|
||
|
|
March 31,
2016 |
|
December 31,
2015 |
||||
|
ASSETS
|
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
145,329
|
|
|
$
|
135,223
|
|
|
Restricted cash
|
11,523
|
|
|
10,725
|
|
||
|
Accounts receivable
|
25,175
|
|
|
33,500
|
|
||
|
Deferred income taxes
|
210
|
|
|
210
|
|
||
|
Prepaid expenses and other current assets
|
4,352
|
|
|
4,219
|
|
||
|
Total current assets
|
186,589
|
|
|
183,877
|
|
||
|
Property and equipment, net
|
231
|
|
|
272
|
|
||
|
Patents, net
|
151,882
|
|
|
162,642
|
|
||
|
Other assets
|
1,111
|
|
|
1,110
|
|
||
|
|
$
|
339,813
|
|
|
$
|
347,901
|
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
||
|
Current liabilities:
|
|
|
|
|
|
||
|
Accounts payable and accrued expenses
|
$
|
14,580
|
|
|
$
|
17,347
|
|
|
Accrued patent investment costs
|
—
|
|
|
1,000
|
|
||
|
Royalties and contingent legal fees payable
|
18,618
|
|
|
14,878
|
|
||
|
Total current liabilities
|
33,198
|
|
|
33,225
|
|
||
|
Deferred income taxes
|
210
|
|
|
210
|
|
||
|
Other liabilities
|
345
|
|
|
311
|
|
||
|
Total liabilities
|
33,753
|
|
|
33,746
|
|
||
|
Commitments and contingencies (Note 5)
|
|
|
|
|
|
||
|
Stockholders’ equity:
|
|
|
|
|
|
||
|
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued or outstanding
|
—
|
|
|
—
|
|
||
|
Common stock, par value $0.001 per share; 100,000,000 shares authorized; 50,458,905 and 50,651,239 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively
|
50
|
|
|
51
|
|
||
|
Treasury stock, at cost, 1,729,408 shares as of March 31, 2016 and December 31, 2015
|
(34,640
|
)
|
|
(34,640
|
)
|
||
|
Additional paid-in capital
|
634,882
|
|
|
633,146
|
|
||
|
Accumulated comprehensive loss
|
(148
|
)
|
|
(215
|
)
|
||
|
Accumulated deficit
|
(298,096
|
)
|
|
(288,131
|
)
|
||
|
Total Acacia Research Corporation stockholders’ equity
|
302,048
|
|
|
310,211
|
|
||
|
Noncontrolling interests in operating subsidiaries
|
4,012
|
|
|
3,944
|
|
||
|
Total stockholders’ equity
|
306,060
|
|
|
314,155
|
|
||
|
|
$
|
339,813
|
|
|
$
|
347,901
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
||||
|
Revenues
|
$
|
24,721
|
|
|
$
|
34,210
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
||
|
Cost of revenues:
|
|
|
|
|
|
||
|
Inventor royalties
|
1,573
|
|
|
9,325
|
|
||
|
Contingent legal fees
|
4,109
|
|
|
4,784
|
|
||
|
Litigation and licensing expenses - patents
|
7,723
|
|
|
8,675
|
|
||
|
Amortization of patents
|
10,760
|
|
|
13,038
|
|
||
|
General and administrative expenses (including non-cash stock compensation expense of $1,735 for the three months ended March 31, 2016 and $3,247 for the three months ended March 31, 2015, respectively)
|
7,994
|
|
|
10,575
|
|
||
|
Research, consulting and other expenses - business development
|
522
|
|
|
997
|
|
||
|
Other
|
1,742
|
|
|
426
|
|
||
|
Total operating costs and expenses
|
34,423
|
|
|
47,820
|
|
||
|
Operating loss
|
(9,702
|
)
|
|
(13,610
|
)
|
||
|
|
|
|
|
|
|
||
|
Total other income (expense)
|
(3
|
)
|
|
228
|
|
||
|
Loss before provision for income taxes
|
(9,705
|
)
|
|
(13,382
|
)
|
||
|
Provision for income taxes
|
(192
|
)
|
|
(170
|
)
|
||
|
Loss including noncontrolling interests in operating subsidiaries
|
(9,897
|
)
|
|
(13,552
|
)
|
||
|
Net (income) loss attributable to noncontrolling interests in operating subsidiaries
|
(68
|
)
|
|
422
|
|
||
|
Net loss attributable to Acacia Research Corporation
|
$
|
(9,965
|
)
|
|
$
|
(13,130
|
)
|
|
|
|
|
|
|
|
||
|
Net loss attributable to common stockholders - basic and diluted
|
$
|
(9,965
|
)
|
|
$
|
(13,345
|
)
|
|
|
|
|
|
||||
|
Basic and diluted loss per common share
|
$
|
(0.20
|
)
|
|
$
|
(0.27
|
)
|
|
|
|
|
|
||||
|
Weighted average number of shares outstanding - basic and diluted
|
49,925,550
|
|
|
49,212,207
|
|
||
|
|
|
|
|
||||
|
Cash dividends declared per common share
|
$
|
—
|
|
|
$
|
0.125
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
||||
|
Net loss including noncontrolling interests in operating subsidiaries
|
$
|
(9,897
|
)
|
|
$
|
(13,552
|
)
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
||
|
Unrealized loss on short-term investments, net of tax of $0
|
—
|
|
|
(143
|
)
|
||
|
Unrealized loss on foreign currency translation, net of tax of $0
|
67
|
|
|
(28
|
)
|
||
|
Reclassification adjustment for losses included in net loss
|
—
|
|
|
84
|
|
||
|
Total other comprehensive loss
|
(9,830
|
)
|
|
(13,639
|
)
|
||
|
Comprehensive (income) loss attributable to noncontrolling interests
|
(68
|
)
|
|
422
|
|
||
|
Comprehensive loss attributable to Acacia Research Corporation
|
$
|
(9,898
|
)
|
|
$
|
(13,217
|
)
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Net loss including noncontrolling interests in operating subsidiaries
|
$
|
(9,897
|
)
|
|
$
|
(13,552
|
)
|
|
Adjustments to reconcile net loss including noncontrolling interests in operating subsidiaries to net cash provided by (used in) operating activities:
|
|
|
|
|
|
||
|
Depreciation and amortization
|
10,803
|
|
|
13,101
|
|
||
|
Non-cash stock compensation
|
1,735
|
|
|
3,247
|
|
||
|
Other
|
69
|
|
|
(12
|
)
|
||
|
|
|
|
|
||||
|
Changes in assets and liabilities:
|
|
|
|
|
|||
|
Restricted cash
|
(798
|
)
|
|
(10,718
|
)
|
||
|
Accounts receivable
|
8,325
|
|
|
(9,839
|
)
|
||
|
Prepaid expenses and other assets
|
(134
|
)
|
|
(702
|
)
|
||
|
Accounts payable and accrued expenses
|
(2,733
|
)
|
|
(2,133
|
)
|
||
|
Royalties and contingent legal fees payable
|
3,740
|
|
|
4,778
|
|
||
|
|
|
|
|
||||
|
Net cash provided by (used in) operating activities
|
11,110
|
|
|
(15,830
|
)
|
||
|
|
|
|
|
|
|
||
|
Cash flows from investing activities:
|
|
|
|
|
|
||
|
Investments in patents/ patent rights
|
(1,000
|
)
|
|
(16,861
|
)
|
||
|
Purchases of property and equipment
|
(4
|
)
|
|
—
|
|
||
|
Purchases of available-for-sale investments
|
—
|
|
|
(13,369
|
)
|
||
|
Maturities and sales of available-for-sale investments
|
—
|
|
|
18,579
|
|
||
|
|
|
|
|
||||
|
Net cash used in investing activities
|
(1,004
|
)
|
|
(11,651
|
)
|
||
|
|
|
|
|
|
|
||
|
Cash flows from financing activities:
|
|
|
|
|
|
||
|
Dividends paid to stockholders
|
—
|
|
|
(6,375
|
)
|
||
|
Proceeds from exercises of stock options
|
—
|
|
|
938
|
|
||
|
|
|
|
|
||||
|
Net cash used in financing activities
|
—
|
|
|
(5,437
|
)
|
||
|
|
|
|
|
|
|
||
|
Increase (decrease) in cash and cash equivalents
|
10,106
|
|
|
(32,918
|
)
|
||
|
|
|
|
|
|
|
||
|
Cash and cash equivalents, beginning
|
135,223
|
|
|
134,466
|
|
||
|
|
|
|
|
|
|
||
|
Cash and cash equivalents, ending
|
$
|
145,329
|
|
|
$
|
101,548
|
|
|
|
|
|
|
||||
|
Supplemental schedule of noncash investing activities:
|
|
|
|
||||
|
Patent acquisition costs included in accrued patent acquisition costs
|
$
|
—
|
|
|
$
|
900
|
|
|
|
●
|
Level 1 - Observable Inputs: Quoted prices in active markets for identical investments;
|
|
|
●
|
Level 2 - Pricing Models with Significant Observable Inputs: Other significant observable inputs, including quoted prices for similar investments, interest rates, credit risk, etc.; and
|
|
|
●
|
Level 3 - Unobservable Inputs: Significant unobservable inputs, including the entity’s own assumptions in determining the fair value of investments.
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
|
2016
|
|
2015
|
||||
|
Numerator (in thousands):
|
|
|
|
|
||||
|
Basic and Diluted
|
|
|
|
|
||||
|
Net loss
|
|
$
|
(9,965
|
)
|
|
$
|
(13,130
|
)
|
|
Total dividends declared / paid
|
|
—
|
|
|
(6,375
|
)
|
||
|
Dividends attributable to common stockholders
|
|
—
|
|
|
6,160
|
|
||
|
Net loss attributable to common stockholders – basic and diluted
|
|
$
|
(9,965
|
)
|
|
$
|
(13,345
|
)
|
|
|
|
|
|
|
||||
|
Denominator:
|
|
|
|
|
||||
|
Weighted-average shares used in computing net loss per share attributable to common stockholders – basic and diluted
|
|
49,925,550
|
|
|
49,212,207
|
|
||
|
|
|
|
|
|
||||
|
Basic and diluted net loss per common share
|
|
$
|
(0.20
|
)
|
|
$
|
(0.27
|
)
|
|
Anti-dilutive equity-based incentive awards excluded from the computation
of diluted loss per share
|
|
2,350,445
|
|
|
71,468
|
|
||
|
For the years ending December 31,
|
|
||
|
Remainder of 2016
|
$
|
32,484
|
|
|
2017
|
40,561
|
|
|
|
2018
|
35,765
|
|
|
|
2019
|
19,412
|
|
|
|
2020
|
6,787
|
|
|
|
Thereafter
|
16,873
|
|
|
|
|
$
|
151,882
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
||||
|
Revenues (in thousands)
|
$
|
24,721
|
|
|
$
|
34,210
|
|
|
New agreements executed
|
12
|
|
|
23
|
|
||
|
Licensing and enforcement programs generating revenues
|
15
|
|
|
18
|
|
||
|
As of Date:
|
|
Trailing Twelve -Month Revenues
|
|
% Change
|
|||
|
|
|
|
|
|
|||
|
March 31, 2016
|
|
$
|
115,548
|
|
|
(8
|
)%
|
|
December 31, 2015
|
|
$
|
125,037
|
|
|
5
|
%
|
|
September 30, 2015
|
|
$
|
118,570
|
|
|
(17
|
)%
|
|
June 30, 2015
|
|
$
|
142,768
|
|
|
(6
|
)%
|
|
March 31, 2015
|
|
$
|
152,508
|
|
|
—
|
%
|
|
•
|
the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee;
|
|
•
|
the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments;
|
|
•
|
fluctuations in the total number of agreements executed each period;
|
|
•
|
the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs;
|
|
•
|
the relative maturity of licensing programs during the applicable periods;
|
|
•
|
other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors; and
|
|
•
|
historically, based on the merits and strength of our operating subsidiary’s patent infringement claims and other factors, many prospective licensees have elected to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as those patent infringement cases approached a court determined trial date.
|
|
•
|
4G Wireless technology
|
|
•
|
Online Auction Guarantee technology
|
|
•
|
Audio Communications Fraud Detection technology
|
|
•
|
Reflective and Radiant Barrier Insulation technology
|
|
•
|
Bone Wedge technology
|
|
•
|
Speech codes used in wireless and wireline systems technology
|
|
•
|
Broadband Communications technology
|
|
•
|
Telematics technology
|
|
•
|
Cardiology and Vascular Device technology
|
|
•
|
Unicondylar Knee Replacement technology
|
|
•
|
DisplayPort and MIPI DSI technology
|
|
•
|
Variable Data Printing technology
(1)
|
|
•
|
Gas Modulation Control Systems technology
|
|
•
|
Wireless Infrastructure and User Equipment technology
|
|
•
|
Lighting Ballast technology
|
|
|
|
|
(1)
|
Initial revenues recognized during the three months ended March 31, 2016
|
|
•
|
3G & 4G Cellular Air Interface and Infrastructure technology
|
|
•
|
Location Based Services technology
|
|
•
|
Audio Communications Fraud Detection technology
|
|
•
|
Oil and Gas Production technology
|
|
•
|
Automotive Safety, Navigation and Diagnostics technology
|
|
•
|
Online Auction Guarantee technology
|
|
•
|
Broadband Communications technology
|
|
•
|
Reflective and Radiant Barrier Insulation technology
|
|
•
|
DisplayPort and MIPI DSI technology
(1)
|
|
•
|
Semiconductor Testing technology
(1)
|
|
•
|
Gas Modulation Control Systems technology
|
|
•
|
Speech codes used in wireless and wireline systems technology
|
|
•
|
Innovative Display technology
|
|
•
|
Super Resolutions Microscopy technology
|
|
•
|
Intercarrier SMS technology
|
|
•
|
Suture Anchors technology
|
|
•
|
Interstitial and Pop-Up Internet Advertising technology
|
|
•
|
Telematics technology
|
|
(1)
|
Initial revenues recognized during the three months ended March 31, 2015
|
|
|
Three Months Ended
March 31, |
|
%
|
|||||||
|
|
2016
|
|
2015
|
|
Change
|
|||||
|
|
|
|
|
|
|
|||||
|
Revenues
|
$
|
24,721
|
|
|
$
|
34,210
|
|
|
(28
|
)%
|
|
Operating costs and expenses
|
34,423
|
|
|
47,820
|
|
|
(28
|
)%
|
||
|
Operating loss
|
(9,702
|
)
|
|
(13,610
|
)
|
|
(29
|
)%
|
||
|
Loss before provision for income taxes
|
(9,705
|
)
|
|
(13,382
|
)
|
|
(27
|
)%
|
||
|
Provision for income taxes
|
(192
|
)
|
|
(170
|
)
|
|
13
|
%
|
||
|
Net (income) loss attributable to noncontrolling interests in operating subsidiaries
|
(68
|
)
|
|
422
|
|
|
(116
|
)%
|
||
|
Net loss attributable to Acacia Research Corporation
|
(9,965
|
)
|
|
(13,130
|
)
|
|
(24
|
)%
|
||
|
•
|
Revenues decreased
$9.5 million
, or
28%
, to
$24.7 million
, as compared to
$34.2 million
in the comparable prior year quarter,
due primarily to a decrease in
the number of agreements executed, partially offset by an increase in the average revenue per agreement in the first quarter of 2016.
|
|
•
|
Loss before income taxes was
$9.7 million
for the three months ended
March 31, 2016
, as compared to
$13.4 million
for the three months ended
March 31, 2015
. The change was due primarily to the
28%
decrease in revenues and the
(28)%
decrease in operating costs, including the following:
|
|
•
|
Cost of Revenues and Other Operating Expenses:
|
|
•
|
Inventor royalties and contingent legal fees, on a combined basis, decreased
$8.4 million
, or
60%
, compared to the
28%
decrease in related revenues for the same periods, due primarily to a greater percentage of revenues generated in the first quarter of
2016
having lower average inventor royalty rates, primarily due to higher average levels of upfront advance recovery related preferred returns, as compared to the portfolios generating revenues in the prior year quarter.
|
|
•
|
Litigation and licensing expenses-patents decreased
$952,000
, or
11%
, to
$7.7 million
, d
ue primarily to a net decrease in litigation support costs associated with upcoming trials.
|
|
•
|
Amortization expense decreased
$2,278,000
, or
17%
, to
$10.8 million
, due to a decrease in scheduled amortization on existing patent portfolios resulting from various patent portfolio impairment charges previously recorded in the fourth quarter of 2015.
|
|
•
|
General and administrative expenses decreased
$2.6 million
, or
24%
, to
$8.0 million
,
due primarily to a net decrease in non-cash stock compensation and personnel costs in connection with head count reduction activities in 2015 and 2016, and a decrease in variable performance-based compensation costs.
|
|
•
|
Other operating expenses were
$1.7 million
as compared to
$426,000
in the comparable prior year quarter. Other operating expenses includes expense accruals for court ordered attorney's fees and settlement and contingency accruals for other matters
.
|
|
•
|
Increases in patent-related legal expenses associated with patent infringement litigation, including, but not limited to, increases in costs billed by outside legal counsel for discovery, depositions, economic analyses, damages assessments, expert witnesses and other consultants, re-exam and i
nter partes review costs,
case-related audio/video presentations and other litigation support and administrative costs could increase our operating costs and decrease our profit generating opportunities;
|
|
•
|
Our patented technologies and enforcement actions are complex and, as a result, we may be required to appeal adverse decisions by trial courts in order to successfully enforce our patents. Moreover, such appeals may not be successful;
|
|
•
|
New legislation, regulations or rules related to enforcement actions, including any fee or cost shifting provisions, could significantly increase our operating costs and decrease our profit generating opportunities.
Increased focus on the growing number of patent-related lawsuits may result in legislative changes which increase our costs and related risks of asserting patent enforcement actions. For instance, the United States House of Representatives passed a bill that would require non-practicing entities that bring patent infringement lawsuits to pay legal costs of the defendants, if the lawsuits are unsuccessful and certain standards are not met;
|
|
•
|
Courts may rule that our subsidiaries have violated certain statutory, regulatory, federal, local or governing rules or standards by pursuing such enforcement actions, which may expose us and our operating subsidiaries to material liabilities, which could harm our operating results and our financial position; and
|
|
•
|
The complexity of negotiations and potential magnitude of exposure for potential infringers associated with higher quality patent portfolios may lead to increased intervals of time between the filing of litigation and potential revenue events (i.e. markman dates, trial dates), which may lead to increased legal expenses, consistent with the higher revenue potential of such portfolios.
|
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2016
|
|
2015
|
|
$
|
|
%
|
|||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
Revenues (in thousands, except percentage change values)
|
|
$
|
24,721
|
|
|
$
|
34,210
|
|
|
$
|
(9,489
|
)
|
|
(28
|
)%
|
|
New agreements executed
|
|
12
|
|
|
23
|
|
|
|
|
|
|||||
|
Average revenue per agreement (in thousands)
|
|
$
|
2,060
|
|
|
$
|
1,487
|
|
|
|
|
|
|||
|
|
|
Three Months Ended
March 31, |
||
|
|
|
2016 vs. 2015
|
||
|
|
|
|
||
|
Change in number of agreements executed
|
|
$
|
(16,361
|
)
|
|
Change in average revenue per agreement executed
|
|
6,872
|
|
|
|
Total change in revenues
|
|
$
|
(9,489
|
)
|
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2016
|
|
2015
|
|
$
|
|
%
|
|||||||
|
|
|
(in thousands, except percentage change values)
|
|||||||||||||
|
Loss before provision for income taxes
|
|
$
|
(9,705
|
)
|
|
$
|
(13,382
|
)
|
|
$
|
3,677
|
|
|
(27
|
)%
|
|
|
Three Months Ended
March 31, |
|
|
|||
|
|
2016 vs. 2015
|
|
%
|
|||
|
|
(in thousands, except percentage values)
|
|||||
|
Decrease in revenues
|
$
|
(9,489
|
)
|
|
(258
|
)%
|
|
Decrease in inventor royalties and contingent legal fees
|
8,427
|
|
|
229
|
%
|
|
|
Decrease in general and administrative expenses
|
2,581
|
|
|
70
|
%
|
|
|
Decrease in litigation and licensing expenses
|
952
|
|
|
26
|
%
|
|
|
Decrease in patent amortization expenses
|
2,278
|
|
|
62
|
%
|
|
|
Other
|
(1,072
|
)
|
|
(29
|
)%
|
|
|
Total change in loss before provision for income taxes
|
$
|
3,677
|
|
|
100
|
%
|
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2016
|
|
2015
|
|
$
|
|
%
|
|||||||
|
|
|
(in thousands, except percentage change values)
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
Inventor royalties
|
|
$
|
1,573
|
|
|
$
|
9,325
|
|
|
$
|
(7,752
|
)
|
|
(83
|
)%
|
|
Contingent legal fees
|
|
$
|
4,109
|
|
|
$
|
4,784
|
|
|
$
|
(675
|
)
|
|
(14
|
)%
|
|
|
|
Three Months Ended
March 31, |
|
%
|
|||
|
|
|
2016 vs. 2015
|
|
||||
|
Inventor Royalties:
|
|
|
|||||
|
Decrease in total revenues
|
|
$
|
(2,605
|
)
|
|
34
|
%
|
|
Decrease in inventor royalty rates
|
|
(72
|
)
|
|
1
|
%
|
|
|
Increase in revenues without inventor royalty obligations primarily due to upfront advance related preferred returns
|
|
(5,075
|
)
|
|
65
|
%
|
|
|
Total change in inventor royalties expense
|
|
$
|
(7,752
|
)
|
|
100
|
%
|
|
Contingent Legal Fees:
|
|
|
|
|
|||
|
Decrease in total revenues
|
|
$
|
(1,408
|
)
|
|
209
|
%
|
|
Decrease in contingent legal fee rates
|
|
682
|
|
|
(101
|
)%
|
|
|
Decrease in revenues without contingent legal fee obligations
|
|
51
|
|
|
(8
|
)%
|
|
|
Total change in contingent legal fees expense
|
|
$
|
(675
|
)
|
|
100
|
%
|
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2016
|
|
2015
|
|
$
|
|
%
|
|||||||
|
|
|
(in thousands, except percentage change values)
|
|||||||||||||
|
Litigation and licensing expenses - patents
|
|
$
|
7,723
|
|
|
$
|
8,675
|
|
|
$
|
(952
|
)
|
|
(11
|
)%
|
|
Amortization of patents
|
|
$
|
10,760
|
|
|
$
|
13,038
|
|
|
$
|
(2,278
|
)
|
|
(17
|
)%
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
2016
|
|
2015
|
|
$
|
|
%
|
|||||||
|
|
|
|
|
|
|
|||||||||
|
General and administrative expenses
|
$
|
6,259
|
|
|
$
|
7,328
|
|
|
$
|
(1,069
|
)
|
|
(15
|
)%
|
|
Non-cash stock compensation expense
|
1,735
|
|
|
3,247
|
|
|
(1,512
|
)
|
|
(47
|
)%
|
|||
|
Total general and administrative expenses
|
$
|
7,994
|
|
|
$
|
10,575
|
|
|
$
|
(2,581
|
)
|
|
(24
|
)%
|
|
|
Three Months Ended
March 31, |
|
|
|||
|
|
2016 vs. 2015
|
|
%
|
|||
|
|
|
|||||
|
Personnel cost reductions due to headcount reductions
|
$
|
(1,586
|
)
|
|
61
|
%
|
|
Variable performance-based compensation costs
|
(534
|
)
|
|
21
|
%
|
|
|
Corporate, general and administrative costs
|
558
|
|
|
(22
|
)%
|
|
|
Non-cash stock compensation expense
|
(1,512
|
)
|
|
59
|
%
|
|
|
Non-recurring employee severance costs
|
493
|
|
|
(19
|
)%
|
|
|
Total change in general and administrative expenses
|
$
|
(2,581
|
)
|
|
100
|
%
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
||||
|
Provision for income taxes (in thousands)
|
$
|
(192
|
)
|
|
$
|
(170
|
)
|
|
Effective tax rate
|
2
|
%
|
|
1
|
%
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
||||
|
Net cash provided by (used in):
|
|
|
|
||||
|
Operating activities
|
$
|
11,110
|
|
|
$
|
(15,830
|
)
|
|
Investing activities
|
(1,004
|
)
|
|
(11,651
|
)
|
||
|
Financing activities
|
—
|
|
|
(5,437
|
)
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
||||
|
Available-for-sale investments, net
|
$
|
—
|
|
|
$
|
5,210
|
|
|
Investments in patents/ patent rights
|
(1,000
|
)
|
|
(16,861
|
)
|
||
|
Purchases of property and equipment
|
(4
|
)
|
|
—
|
|
||
|
Net cash provided by investing activities
|
$
|
(1,004
|
)
|
|
$
|
(11,651
|
)
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
|
|
||
|
Dividends paid to stockholders
|
$
|
—
|
|
|
$
|
(6,375
|
)
|
|
Proceeds from exercises of stock options
|
—
|
|
|
938
|
|
||
|
Net cash used in financing activities
|
$
|
—
|
|
|
$
|
(5,437
|
)
|
|
|
Payments Due by Period (In thousands)
|
||||||||||||||||||
|
Contractual Obligations
|
Total
|
|
Less than 1 year
|
|
1-3 years
|
|
3-5 years
|
|
More than 5 years
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Operating leases, net of guaranteed sublease income
|
$
|
4,960
|
|
|
$
|
942
|
|
|
$
|
2,569
|
|
|
$
|
1,449
|
|
|
$
|
—
|
|
|
EXHIBIT
NUMBER
|
EXHIBIT
|
|
|
|
|
3.1
|
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-k filed on March 28, 2016).
|
|
31.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
31.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
32.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
32.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
101
|
Interactive Data Files Pursuant to Rule 405 of Regulation S-T
|
|
|
ACACIA RESEARCH CORPORATION
|
|
|
|
|
|
/
s/ Marvin Key
|
|
|
By: Marvin Key
|
|
|
Interim Chief Executive Officer
|
|
|
(Principal Executive Officer and Duly Authorized Signatory)
|
|
|
|
|
|
/s/ Clayton J. Haynes
|
|
|
By: Clayton J. Haynes
|
|
|
Chief Financial Officer and Treasurer
|
|
|
(Principal Financial and Accounting Officer)
|
|
EXHIBIT
NUMBER
|
EXHIBIT
|
|
3.1
|
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-k filed on March 28, 2016).
|
|
31.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
31.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
32.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
32.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
101
|
Interactive Data Files Pursuant to Rule 405 of Regulation S-T.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|